Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONQUEST: Platform Study for Scleroderma-ILD
NCT06195072Phase 2Recruiting
- Start
- Apr 2024
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
A Phase 2 trial of amlitelimab, nerandomilast in interstitial lung disease secondary to systemic sclerosis (SSc-ILD). Started Apr 2024; status: recruiting.
02
Drugs
amlitelimabnerandomilast
03
Conditions
interstitial lung disease secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on NCT06195072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06195072.